Additional Information

Description

Odefsey® is a fixed-dose combination tablet containing emtricitabine (200 mg), rilpivirine (25 mg), and tenofovir alafenamide (25 mg). This combination is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, as part of a comprehensive antiretroviral therapy regimen. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs), while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Each tablet of Odefsey® is film-coated and should be taken once daily with food. The combination of these three drugs provides potent HIV suppression while minimizing the risk of resistance, especially when used in treatment-naïve individuals. It is important to take the medication as prescribed and in combination with other HIV medications to maintain viral suppression.

Common side effects of Odefsey® include headache, diarrhea, nausea, and insomnia. Serious adverse effects can include liver problems, depressive disorders, and the development of resistance to the drugs if not taken as prescribed. Monitoring of liver function and renal health is advised during treatment.